Clinical Trial: A Study of DAT-2645 in Patients With BRCA1/2 Mutations or HRD-Positive Ovarian Cancer

U.S., June 17 -- ClinicalTrials.gov registry received information related to the study (NCT07652073) titled 'A Study of DAT-2645 in Patients With BRCA1/2 Mutations or HRD-Positive Ovarian Cancer' on June 11.

Brief Summary: This is a Phase II, multicenter, single-arm dose expansion trial planned to enroll up to 30 subjects with advanced or metastatic ovarian cancer. The Objective is to conduct a preliminary evaluation of the efficacy, the safety, tolerability and PK profile of DAT-2645

Study Start Date: June 15

Study Type: INTERVENTIONAL

Condition: Advanced or Metastatic Ovarian Cancer

Intervention: DRUG: DAT-2645 tablet

Oral administration with 21 days each cycle

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Danatlas Pharmaceuti...